SLx-2119

911417-87-3

C26H24N6O2

DMSO : >= 29 mg/mL (64.09 mM)

TGF-beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage

SLx-2119 (KD-025) is a selective inhibitor of ROCK2 with an IC₅₀ of 105 nM. IC50 & Target: IC50: 105 nM (ROCK2)^[1] In Vitro: SLx-2119 (40 uM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays^[1]. In Vivo: SLx-2119 (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. SLx-2119 is at least as efficacious in aged, diabetic or female mice, as in normal adult males^[2].